NAV — Navco Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$1.43m
- CA$1.51m
Annual income statement for Navco Pharmaceuticals, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2022 June 30th | 2023 September 30th | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Depreciation and Amortization | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 0.1 | 2.15 |
| Operating Profit | -0.1 | -2.15 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -0.094 | -2.15 |
| Net Income After Taxes | -0.094 | -2.15 |
| Net Income Before Extraordinary Items | ||
| Net Income | -0.094 | -2.15 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -0.094 | -2.15 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.036 | -0.049 |